ALBANY, N.Y.--(BUSINESS WIRE)--Feb. 13, 2006--Albany Molecular Research, Inc. (Nasdaq: AMRI) today reported financial results for the quarter and year ending December 31, 2005. Financial and operating highlights from the fourth quarter and full year include: Total contract revenue in the fourth quarter of $32.9 million, exceeding the company's estimated range of $28 to $31 million.
